Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 61Recruiting 26Terminated 25Active not recruiting 19Withdrawn 6Unknown 4Suspended 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

ibrutinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Melphalan 1JNJ-64619178 1JNJ-64264681 1Busulfan 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Myelodysplastic Syndromes × fludarabine × Clear all
NCT05674539 2025-02-10

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3 Enrolling by invitation
200 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡